Central Nervous System Disorder Drugs Market - Global
Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
The
market for central nervous system disorder drugs comprise of drugs used for the
treatment of diseases affecting the brain or spinal cord such as epilepsy,
Parkinson’s disease, Alzheimer’s disease, depression, anxiety and bipolar
disorders. Epilepsy is a chronic brain disorder characterized by recurring
seizures. Parkinson’s disease is a degenerative CNS disorder associated with
symptoms including tremor, rigidity, akinesia and bradykinesia. It is reported
by Parkinson’s disease Foundation that as of now 7-10 million people are
affected with Parkinson’s disease across the globe. These diseases are
generally caused by neurodegeneration, autoimmune disorders, trauma, tumors and
vascular disorders.
To Read The Complete Report with
TOC:-
The
market for CNS disorders is categorized into three segments namely psychiatry,
neurology and pain drugs market. Psychiatry drugs market is further segmented
into anxiety, depression, bipolar disorders, schizophrenia and ADHD (attention
deficit hyperactivity disorder). Neurology drugs market is divided into
migraine, epilepsy, Parkinson’s disease, multiple sclerosis, narcolepsy and and
Alzheimer’s disease. Pain management drugs market segment comprises of drugs
used to treat pain associated with CNS disorders. Among these psychiatry
segment holds the largest share accounting for more than 40% followed by
neurology and pain segment.
Rapidly
increasing geriatric population base resulting in an elevated incidence levels
of CNS disorders such as Alzheimer’s disease, Parkinson’s disease,
schizophrenia and multiple disorders is one of the key factors driving the
growth of the market for CNS disorders.. Currently, there is no drug to cure
Alzheimer’s disease, the available medicines only treat the severity of
symptoms and improve the quality of life to some extent. That is why companies
such as Eli Lilly, Baxter International and Novartis AG are investing heavily
in research and development in order to accelerate the treatment of Alzheimer’s
disease.
To Buy a Copy Of This Report:-
Geographically,
North America holds the largest share of the total market of CNS disorders
followed by Europe and Asia-Pacific. Asia-Pacific is projected to grow at a
CAGR more than other regions on account of high prevalence of diseases such as
epilepsy, Parkinson’s disease and Alzheimer’s disease. As of 2012, WHO (world
health organization) suggests that around 50 million people are suffering from
epilepsy worldwide, most of them (approximately 80%) belong to developing
nations.
Contact:-
M/s
Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment